

# Occurrence of relative bradycardia and relative tachycardia in individuals diagnosed with COVID-19

Aravind Natarajan,\* Hao-Wei Su, and Conor Heneghan

*Fitbit Research, 199 Fremont St, Fl #14, San Francisco, CA 94105*

(Dated: January 28, 2022)

## Abstract

### ***Background:***

The COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become one of the worst global pandemics of the century causing tremendous human and economic suffering worldwide. While considered a respiratory disease, COVID-19 is known to cause cardiac complications. Wearable devices are well equipped to measure heart rate continuously and their popularity makes them valuable devices in the field of digital health. In this article, we use Fitbit devices to examine resting heart rate from individuals diagnosed with COVID-19 <sup>a</sup>

### ***Methods:***

The Fitbit COVID-19 survey was conducted from May 2020 - June 2021. We collected resting heart rate data from 7,200 individuals (6,606 symptomatic, 594 asymptomatic) diagnosed with COVID-19 between March 2020 - December 2020, as well as from 463 individuals diagnosed with influenza between January 2020 - December 2020. Data from healthy individuals served as a control, in order to model the seasonal variation. We also computed heart rate variability and respiratory rate data for symptomatic COVID-19.

### ***Findings:***

Resting Heart Rate is elevated during COVID-19 symptom onset, with average peak increases relative to the baseline of  $1.8\% \pm 0.1\%$  ( $3.4\% \pm 0.2\%$ ) for females (males), where the quoted numbers are mean and standard error of the mean. After the initial peak, the resting heart rate decreased and reached a minimum on average  $\approx 13$  days after symptom onset. The minimum value relative to the baseline is more negative for females ( $-1.75\% \pm 0.1\%$ ) compared to males ( $0.08\% \pm 0.2\%$ ). The resting heart rate then increased, reaching a second peak on average  $\approx 28$  days from symptom onset, before falling back to the baseline  $\approx 112$  days from symptom onset. All estimates vary with disease severity.

### ***Interpretation:***

The resting heart rate is modified for several months following a COVID-19 diagnosis. Interestingly, this effect is seen with seasonal influenza also, although the bradycardia minimum and the second tachycardia peak are often more pronounced in the case of symptomatic COVID-19. By computing resting heart rate daily, wearable devices can contribute to monitoring wellness during recovery from COVID-19, and seasonal influenza.

**Funding:** A.N., H.-W.S., and C.H. are supported by Fitbit Research, Google LLC.

## 1     **Research in Context:**

### 3     ***Evidence before this study:***

4     We searched PubMed, Google, and Google Scholar for research articles published in  
5     English up to Oct 31, 2021, using common search terms such as “bradycardia and COVID-  
6     19”, “cardiac complications and COVID-19”, etc. Articles were also retrieved by searching  
7     through citations of known literature. It is known that COVID-19 can cause cardiac com-  
8     plications such as bradycardia and arrhythmias. Using data from commercially available  
9     wearable devices, it has been shown previously that the resting heart is elevated during  
10    symptom onset, then decreases reaching a minimum, before rising again to attain a second  
11    peak, before finally returning to the baseline.

### 12    ***Added value of this study:***

13    We present results from the largest (to our knowledge) dataset considered to-date, involv-  
14    ing 7200 participants (6606 symptomatic and 594 asymptomatic) diagnosed with COVID-19.  
15    We also present results from 463 individuals diagnosed with influenza. Our large dataset  
16    allows us to perform more detailed examinations by age, disease severity, and sex. We also  
17    discuss the time evolution of heart rate variability and respiratory rate. The heart rate  
18    variability shows a similar time evolution as the resting heart rate but with opposite phase,  
19    while the respiratory rate decreases monotonously following the peak at symptom onset.

### 20    ***Implications of all the available evidence:***

21    The results presented in this work show that commercially available trackers and smart-  
22    watches can help in monitoring heart health in the weeks and months following a COVID-19  
23    diagnosis. An estimate of the amplitude of the bradycardia dip may provide information  
24    valuable to critical care.

## 25    **I. INTRODUCTION**

26    Cardiac complications are known to be associated with the COVID-19 disease caused by  
27    the novel Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2)<sup>1-8</sup>. Cardiac

<sup>a</sup> This feature is not intended to diagnose or treat any medical condition and should not be relied on for any medical purposes. It is provided to Fitbit users to help manage well-being.

28 injury, heart failure, and arrhythmias have been recorded in patients diagnosed with COVID-  
29 19<sup>1,5,9,10</sup>.

30 An unusual feature that is sometimes seen in patients diagnosed with COVID-19 is the  
31 appearance of bradycardia, i.e. slow heart rate, or heart rate not increasing as expected  
32 with body temperature<sup>11–14</sup>. Amaratunga et al.<sup>15</sup> found bradycardia in a study of 4 patients  
33 with confirmed COVID-19, with minimum pulse rates in the range 42–49 beats per minute.  
34 Amir et al.<sup>16</sup> reported 6 cases of bradycardia among patients diagnosed with COVID-19,  
35 with 4 patients developing complete atrioventricular block. Elikowski et al.<sup>17</sup> presented  
36 clinical data of 19 patients diagnosed with COVID-19 who exhibited sinus bradycardia, in  
37 some cases showing heart rates as low as 32 bpm during daily hours. Srinivasan et al.<sup>18</sup>  
38 discussed 6 cases of patients who were diagnosed with COVID-19 and admitted with normal  
39 sinus rhythm, and who subsequently developed sinus bradycardia with daytime heart rates  
40 ranging from 35–48 bpm. In a study of 97 patients with a non-severe presentation of  
41 COVID-19, Zhou et al.<sup>19</sup> found significant sinus bradycardia (below 50 bpm) in 7.2% of  
42 cases. Guo et al.<sup>20</sup> reported ventricular tachycardia (VT) or ventricular fibrillation (VF) in  
43 11 out of 187 patients with confirmed COVID-19 and found that elevated levels of troponin  
44 T were correlated with VT/VF. Inflammatory damage due to cytokines has been suggested  
45 as a possible explanation for cardiac involvement with COVID-19<sup>17,21–23</sup>.

46 Commercially available wearable devices have been shown to be useful in early detection  
47 of COVID-19 and for monitoring symptoms<sup>24–29</sup>. Radin et al.<sup>30</sup> studied resting heart rate  
48 (henceforth RHR) data from Fitbit devices to investigate long term changes following symp-  
49 tom onset. RHR is typically elevated around symptom onset. We use the term “relative”  
50 to indicate that the RHR is elevated/decreased relative to the baseline value for that indi-  
51 vidual, although the RHR is not necessarily above/below the clinical threshold guideline<sup>31</sup>.  
52 They also found the RHR exhibits a dip which we refer to as transient relative bradycardia  
53 provided the RHR is below the baseline value. The RHR dip was followed by a second ele-  
54 vated RHR peak. They found that the RHR was elevated for up to 79 days from symptom  
55 onset.

56 In this article, we obtain results consistent with the findings of Radin et al., and ex-  
57 pand upon existing work in a number of ways. We study a much larger sample size than  
58 previously considered. We investigate how the resting heart range changes, for male and  
59 female individuals, and for individuals with severe, mild or asymptomatic presentations of

60 COVID-19. We also consider individuals diagnosed with the seasonal influenza (henceforth  
61 “flu”). We tabulate the expected amplitudes of the maxima/minima, as well as the time  
62 taken to reach these maxima/minima, and the estimated widths of the peaks/troughs. We  
63 examine how these parameters vary with age, sex, and disease severity. We also study heart  
64 rate variability and respiratory rate and how these metrics vary with time.

## 65 II. METHODS

### 66 A. Survey Data

67 The Fitbit COVID-19 survey was conducted from May 21, 2020 to June 10, 2021, and  
68 collected data from participants residing in the USA or Canada. Participants provided in-  
69 formation on whether they were diagnosed with COVID-19 or flu, as well as the test date,  
70 symptoms, and the start date of symptoms. Participants could optionally provide infor-  
71 mation about their age, sex, body mass index, and information on underlying conditions.  
72 Individuals diagnosed with COVID-19 also indicated the severity of the disease which could  
73 be (i) severe, indicating that they required hospitalization, (ii) mild, indicating that they  
74 recovered at home, or (iii) asymptomatic. The survey and associated marketing and recruit-  
75 ment materials were approved by an Institutional Review Board (Advarra). The participants  
76 provided electronic informed consent for their data to be used for research. In this study,  
77 we consider data from Fitbit users who reported testing positive for COVID-19 in the date  
78 range March 1 - Dec 31, 2020, as well as users who reported testing positive for flu in the  
79 date range Jan 1 - Dec 31, 2020. There were 11,918 participants who tested positive for  
80 COVID-19 (mean age = 40.8 yr, std. dev. = 12.4 yr, 79.0% female) in our dataset, and  
81 865 participants who tested positive for flu (mean age = 41.7 yr, std. dev. = 13.3 yr,  
82 78.2% female). We randomly select 1,000 users who did not report a positive test for either  
83 COVID-19 or flu as a control group (mean age = 45.3 yr, std. dev. = 13.9 yr, 71.6% fe-  
84 male). Table I shows the prevalence of symptoms (self reported) for COVID-19 and flu, for  
85 male and female participants (for COVID-19, we also separate by disease severity). Some  
86 symptoms such as fatigue, headache and body ache are common for both COVID-19 and  
87 flu. By contrast, a decrease in taste and/or smell is more likely in the case of COVID-19  
88 (72.6% female, 59.8% male) compared to flu (21.2% female, 11.6% male). Fever is more

89 common with flu (81.3% female, 76.8% male) compared to COVID-19 (51.4% female, 58%  
90 male). Fig. 1 shows the distribution of positive cases for flu and COVID-19, where the  
91 horizontal axis is the test date, and only positive cases are shown. Cases of flu peaked in  
92 March 2020, while COVID-19 cases peaked much later.

## 93 B. RHR data

94 We measure the RHR from participants in our study, collected using Fitbit devices. The  
95 “resting heart rate” as defined by Fitbit is the value closest to the heart rate measured when  
96 lying down just before waking up in the morning<sup>32</sup>.

97 RHR is computed using heart rate data during sleep when sleep data is available, and  
98 a proprietary algorithm is utilized to predict the RHR from the time series heart rate data  
99 during sleep. If sleep data is unavailable, RHR is computed using wake time heart rate data,  
100 at times when no activity is detected. The RHR is also processed with a Kalman filter which  
101 serves to smooth the waveform. Note that the RHR is not the minimum value of heart rate.

## 102 C. Time variation of the RHR data

103 Let  $D_0$  be the date of symptom onset for symptomatic individuals (and the test date  
104 for asymptomatic individuals). Thus for symptomatic individuals,  $D_{-1}$  is one day prior  
105 to the appearance of symptoms, and  $D_{+1}$  is one day post appearance of symptoms. We  
106 computed the mean value  $\langle RHR \rangle$  for each individual by averaging the RHR values from  
107  $D_{-90}$  to  $D_{-15}$ . We discard data from participants who have fewer than 30 measurements in  
108 this time window. With this data sufficiency condition, our dataset contains 463 individuals  
109 with the flu, and 7200 individuals with COVID-19 (6606 symptomatic, 594 asymptomatic).  
110 We compute the fractional change in RHR  $\xi$  from days  $D_{-14}$  to  $D_{+180}$  as:

$$\xi(d) = \frac{RHR(d) - \langle RHR \rangle}{\langle RHR \rangle}, \quad (1)$$

111 where  $d$  is a variable indicating day index.

Symptom	Mild (fem.)	Mild (male)	Severe (fem.)	Severe (male)	Flu (fem.)	Flu (male)
Fatigue	0.847	0.761	0.885	0.816	0.843	0.689
Headache	0.793	0.640	0.789	0.618	0.661	0.415
Decrease in taste/smell	0.727	0.598	0.701	0.592	0.211	0.116
Congestion	0.715	0.571	0.503	0.342	0.541	0.512
Body ache	0.689	0.666	0.793	0.684	0.818	0.677
Cough	0.652	0.627	0.784	0.730	0.731	0.616
Chills	0.532	0.557	0.713	0.632	0.734	0.604
Fever	0.501	0.563	0.749	0.796	0.813	0.768
Sore throat	0.498	0.385	0.418	0.342	0.560	0.378
Loss of appetite	0.472	0.345	0.701	0.638	0.440	0.293
Shortness of breath	0.432	0.347	0.871	0.836	0.396	0.299
Chest pain	0.401	0.284	0.687	0.533	0.334	0.244
Diarrhea	0.399	0.319	0.524	0.454	0.192	0.189
Neck pain	0.296	0.186	0.322	0.191	0.193	0.116
Hoarse voice	0.280	0.179	0.320	0.303	0.279	0.110
Eye pain	0.232	0.161	0.232	0.197	0.106	0.067
Stomach ache	0.225	0.115	0.290	0.118	0.130	0.104
Confusion	0.178	0.135	0.368	0.349	0.114	0.140
Vomiting	0.089	0.044	0.271	0.118	0.115	0.067
Rash	0.067	0.034	0.131	0.066	0.029	0.037
Swelling in fingers/toes	0.044	0.022	0.133	0.079	0.032	0.043

TABLE I. Prevalence of symptoms, for COVID-19 (mild/severe) and flu, for male and female participants.

#### 112 **D. Controlling for the seasonality of resting heart rate**

113 The RHR has a known seasonal modulation. In a study of 200,000 individuals wearing  
 114 Fitbit devices and residing in the United States, Quer et al.<sup>33</sup> found a change in the popu-




FIG. 1. Incidence of Flu (top) and COVID-19 (bottom) in the year 2020, from the Fitbit COVID-19 survey.

115 lation's average RHR by 2 beats per minute (bpm). In the Northern hemisphere, the RHR  
116 peaks in the first week of January and reaches its minimum at the end of July.

117 Since all participants in our study reside in the USA or Canada, we assume that they are  
118 subject to the same seasonal trends. We use the control group to estimate how RHR varies  
119 with the time of year, by applying Eq. 1 to obtain  $\xi_{\text{control}}$  as follows:

120 1. Randomly sample a date from the COVID-19 or flu distribution and set to  $D_0$  (date



Symbol	Description
$N$	Sample size
$A_{t1}$	Amplitude of the first relative tachycardia peak
$A_b$	Amplitude of the relative bradycardia trough
$A_{t2}$	Amplitude of the second relative tachycardia peak
$T_{t1}$	Time from symptom onset to first relative tachycardia peak
$T_b$	Time from symptom onset to relative bradycardia trough
$T_{t2}$	Time from symptom onset to second relative tachycardia peak
$W_{t1}$	Full width at half maximum of first relative tachycardia peak
$W_b$	Full width at half minimum of relative bradycardia trough only if $A_b < 0$
$W_{t2}$	Full width at half maximum of second relative tachycardia peak

TABLE II. Description of parameters.

121 of symptom onset).

122 2. Compute  $\xi_{\text{control}}(d)$  using Eq. 1 from the control group for dates  $d$  relative to  $D_0$ .

123 We may then subtract out the seasonality to find the effect of illness on RHR:

$$\Delta\xi = \xi - \xi_{\text{control},\alpha}, \quad (2)$$

124 where  $\alpha$  may be flu or COVID-19. Note that  $\xi_{\text{control}}$  must be computed twice: once for the  
 125 COVID-19 distribution, and once for the flu distribution. To compute  $\Delta\xi(d)$  for a given  
 126 individual, we would use the appropriate  $\xi_{\text{control},\alpha}$  depending on whether the participant was  
 127 diagnosed with flu or COVID-19.

## 128 E. Estimation of parameters

129 We estimate a number of parameters from the time variation of  $\Delta\xi$ . These are sum-  
 130 marized in Table II. The waveforms for  $\xi$  and  $\xi_{\text{control}}$  are linearly interpolated with a step  
 131 size of 0.2 days. The waveforms are then smoothed with a Savitzky–Golay filter with a  
 132 window length of 7 days. We compute  $\Delta\xi$  from the smoothed waveforms, and estimate the  
 133 peaks/troughs by means of a peak detection algorithm. We also report an estimated error  
 134 on the parameter values using the jackknife technique<sup>34,35</sup>.

## 135 **F. Heart Rate Variability and Respiratory Rate**

136 Details on how Fitbit devices compute respiratory rate and heart rate variability have  
137 been previously published<sup>28,36</sup>. In this article, we consider RMSSD computed in 5 minute  
138 windows between the hours of midnight and 6 am. The median of the measurements is then  
139 reported. For the respiratory rate calculation, we first compute the power spectral density  
140 of interbeat intervals in 5 minute windows between the hours of midnight and 7 am. The  
141 measurements are then averaged, and the respiratory rate is estimated from the averaged  
142 power spectral density. We subtract out the seasonality of the RMSSD and respiratory rate  
143 in a similar manner to the RHR, with the addition of a median filter (with a period of 7  
144 days). The median filter was necessary because the RMSSD and respiratory rate waveforms  
145 are not smoothed by a Kalman filter, and are hence noisier than the RHR.

## 146 **G. Code**

147 All computations are performed using standard Python libraries.

## 148 **III. RESULTS**

### 149 **A. Change in RHR following a Flu / COVID-19 diagnosis**

150 Fig. 2 shows the fractional change in RHR for flu and COVID-19, for symptomatic  
151 individuals. Subplot (a) compares  $\xi$  and  $\xi_{\text{control}}$  for flu, while subplot (b) compares  $\xi$  and  
152  $\xi_{\text{control}}$  for COVID-19. The horizontal axis  $D_n$  is the date relative to the date when symptoms  
153 first appear ( $n < 0$  are prior to symptom onset, while  $n > 0$  are after symptom onset.  $D_0$   
154 is the date when symptoms first present).  $\xi$  and  $\xi_{\text{control}}$  are averaged over all individuals  
155 for a specific  $D_n$ . Subplot (c) shows  $\Delta\xi$ , i.e. the excess fractional change in RHR after the  
156 seasonal variation has been subtracted. From subplot (c), we infer the following:

- 157 1. The excess fractional change in RHR, i.e.  $\Delta\xi$  is elevated on average during the onset of  
158 symptoms.  $\Delta\xi$  reaches a peak value  $A_{t1}$  at a time  $T_{t1}$  days from the onset of symptoms.  
159 This is the first transient relative tachycardia.
- 160 2. Following the peak,  $\Delta\xi$  decreases, reaching a minimum value  $A_b$  at a time  $T_b$  days




FIG. 2. Fractional change in RHR ( $\xi$ ), for individuals diagnosed with flu (a) and COVID-19 (b), along with the expected seasonal variation ( $\xi_{\text{control}}$ ). (c) shows the excess fractional change in RHR ( $\Delta\xi$ ) for flu and COVID-19. The parameters shown in (d) are defined in Table II.

161 from the onset of symptoms. If  $A_b < 0$ , we refer to the trough as transient relative  
 162 bradycardia.

163 3. Following the minimum,  $\Delta\xi$  increases again, reaching a second peak  $A_{t2}$  at a time  $T_{t2}$   
 164 days from symptom onset. This is the second transient relative tachycardia.

165 4. Past  $T_{t2}$ ,  $\Delta\xi$  decreases and eventually falls to zero, indicating that the RHR variation

166

is no longer due to illness.

167 The parameters  $A_{t1}$ ,  $A_b$ ,  $A_{t2}$ ,  $T_{t1}$ ,  $T_b$ ,  $T_{t2}$ ,  $W_{t1}$ ,  $W_b$ , and  $W_{t2}$  are marked in subplot (d), and  
 168 described in Table II.




FIG. 3. Excess fractional change in RHR ( $\Delta\xi$ ), variation with severity and sex: (a) shows  $\Delta\xi$  for severe, mild, and asymptomatic COVID-19, as well as flu. (b) shows  $\Delta\xi$  for male and female individuals diagnosed with flu. (c) and (d) show  $\Delta\xi$  for male and female participants, for the cases for severe and mild COVID-19 respectively.

169

Fig. 3 shows the excess fractional change in RHR ( $\Delta\xi$ ) for COVID-19 and flu, for varying

Disease	Sex	$N$	$A_{t1}$	$A_b$	$A_{t2}$
COVID-19	F	5183	$1.78 \pm 0.08$	$-1.75 \pm 0.10$	$1.81 \pm 0.08$
COVID-19	M	1411	$3.39 \pm 0.18$	$0.08 \pm 0.18$	$2.80 \pm 0.17$
Flu	F	360	$2.60 \pm 0.32$	$-0.57 \pm 0.33$	$0.96 \pm 0.30$
Flu	M	103	$4.28 \pm 0.67$	$0.66 \pm 0.72$	$1.94 \pm 0.58$

TABLE III. Estimation of peak amplitudes.  $N$  is the sample size. Estimates are mean and jackknife standard error of the mean.

Age (yr)	Sex	$N$	$A_{t1}$	$A_b$	$A_{t2}$	$T_{t1}$	$T_b$	$T_{t2}^*$	$W_{t1}$	$W_b$	$W_{t2}$
20-29	F	994	1.9	-2.7	1.6	2	11.4	25.8	5	8.8	32.8
30-39	F	1627	1.8	-2.1	1.7	2	11.6	27.4	5	9.4	33.2
40-49	F	1305	1.4	-1.8	1.6	1.8	12	27	4.8	10	35.6
50-59	F	842	2.3	-0.8	2.4	2.4	14.6	37.8	6	7.4	48
$\geq 60$	F	364	2	-1.6	2	2.6	15.6	38.6	7.6	6.8	53
20-29	M	178	3.5	-1.6	2.5	2.6	11.8	33.8	6.4	7	44
30-39	M	392	3.7	-0.4	2.7	2.4	14.2	27.6	6.8	3.2	55.6
40-49	M	370	3.4	-0.2	2.4	2.6	16.6	28.8	9.4	2	43.8
50-59	M	275	3	0.6	3.7	3	17	28.8	13.2	-	36
$\geq 60$	M	175	3.8	1	3.5	5.6	15.6	27.6	12.4	-	53.8

TABLE IV. Estimation of parameters, by age.

\* Values of  $T_{t2}$  are only approximate due to noise and the large width of the second relative tachycardia peak.

170 severity, and for male and female individuals. Subplot (a) shows the effect of severity on  
171  $\Delta\xi$ . The magenta curve is plotted for severe cases (i.e cases that required hospitalization).  
172 The brown curve shows mild cases, while the green curve is plotted for asymptomatic cases.  
173 The blue curve shows  $\Delta\xi$  for flu. The amplitudes of the two relative tachycardia peaks  $A_{t1}$   
174 and  $A_{t2}$  are much larger in the case of severe COVID-19. The bradycardia dip ( $A_b$ ) is more  
175 pronounced in the case of mild COVID-19. The first relative tachycardia peak amplitude  
176 ( $A_{t1}$ ) is larger for flu compared to mild or asymptomatic COVID-19, while the second

Severity	Sex	$N$	$A_{t1}$	$A_b$	$A_{t2}$	$T_{t1}$	$T_b$	$T_{t2}^*$	$W_{t1}$	$W_b$	$W_{t2}$
Severe	F	221	4	-0.9	4.4	5	16.4	38.4	10	3.8	46.8
Severe	M	81	9.1	0.8	6.4	9.2	18.2	37.4	11.8	-	51.2
Mild	F	4943	1.7	-1.8	1.5	2	12.4	28.2	5.2	9.6	37
Mild	M	1326	3.3	0	2.7	2.8	15	28.2	7.8	-	41.4
Asymptomatic	F	452	0.7	-0.7	1.2	0	5	21.8	3.2	8.6	35.6
Asymptomatic	M	142	0.6	-0.7	0.8	1	8.8	27	5.8	5.4	8
Flu	F	360	2.6	-0.6	0.96	2.4	11	26.8	6.4	4.6	29.2
Flu	M	103	4.3	0.66	1.45	2.8	10.2	15.6	8.4	-	59.6

TABLE V. Estimation of parameters, by severity.

\* Values of  $T_{t2}$  are only approximate due to noise and the large width of the second relative tachycardia peak.

177 tachycardia peak is similar in the cases of flu and asymptomatic COVID-19. For the cases  
 178 of severe, mild, asymptomatic, and flu respectively, we find  $\Delta\xi$  falls to zero approximately  
 179 118, 112, 79, and 71 days after the onset of symptoms (or test date for asymptomatic cases).

180 Subplot (b) shows the difference between male and female individuals who were diagnosed  
 181 with flu. Similar to the case of COVID-19, the peak amplitudes  $A_{t1}$  and  $A_{t2}$  are higher for  
 182 males compared to females. The trough amplitude  $A_b$  is lower for females. Subplots (c) and  
 183 (d) shows the variation of  $\Delta\xi$  for male and female individuals, for severe and mild COVID-19  
 184 cases respectively. In both cases, the peak amplitudes  $A_{t1}$  and  $A_{t2}$  are higher for males, for  
 185 both severe and mild cases of COVID-19. The minimum amplitude  $A_b$  on the other hand is  
 186 lower in females than in males, and is more negative for mild cases of COVID-19 compared  
 187 to severe cases.

188 Table III shows the estimated values of the amplitudes for the RHR minimum ( $A_b$ ) and  
 189 the two maxima ( $A_{t1}$  and  $A_{t2}$ ), along with jackknife estimated standard errors. Table IV  
 190 shows the estimated values of the various parameters, for female and male participants, and  
 191 for different ages. Each peak/trough is characterized by 3 parameters: the amplitude, time  
 192 from symptom onset, and full width at half maximum/minimum. The 2 relative tachycardia  
 193 peaks are parameterized by  $(A_{t1}, T_{t1}, W_{t1})$  and  $(A_{t2}, T_{t2}, W_{t2})$ , while the minimum is param-  
 194 eterized by  $(A_b, T_b, W_b)$ . Note that  $W_b$  is only defined when  $A_b < 0$  indicating relative




FIG. 4. Parameters describing the time evolution of the RHR, from Table V, for different age groups, for male (black) and female (red) individuals. Jackknife error bars represent the standard error of the mean. Subplot for  $T_{t2}$  is not shown.

195 bradycardia. Table V shows the estimated values of the parameters for male and female  
 196 participants, for severe, mild, and asymptomatic COVID-19 presentations, as well as for flu.  
 197 Fig. 4 shows the estimated mean values of these parameters for different age groups, for  
 198 male (black) and female (red) individuals.




FIG. 5. (a) Fraction of individuals with  $\Delta RHR \leq x$  in the relative bradycardia window (red points), where  $x$  is a threshold, compared to the fraction that could be expected due to chance (green points). (b) shows the fraction of individuals with  $\Delta RHR \geq x$  in the relative tachycardia window (red points), compared to the fraction that could be expected due to chance (green points).  $\Delta RHR$  is the excess RHR compared to the control window. Error bars show standard error of the mean.



## 199 B. Relative bradycardia and relative tachycardia

200 Let us now quantify the prevalence of relative bradycardia and relative tachycardia. To do  
201 this, we define the following 4 windows each of which are 15 days long (starting and ending  
202 dates inclusive, and  $D_0$  is the date when symptoms present, only symptomatic individuals  
203 included):

- 204 • “Control” window from  $D_{-45}$  to  $D_{-31}$ .
- 205 • Presumed “healthy” window from  $D_{-30}$  to  $D_{-16}$ .
- 206 • Presumed “relative bradycardia” window from  $D_{+7}$  to  $D_{+21}$ .
- 207 • Presumed “relative tachycardia” window from  $D_{+22}$  to  $D_{+36}$ .

208 The healthy and control windows are expected to contain data when participants are  
209 healthy. The RHR is averaged over each window, and we only consider participants who  
210 have 15 days of data in each window. Let  $\Delta RHR_w$  be the difference between the RHR  
211 averaged over window  $w$  and the RHR averaged over the control window:

$$\Delta RHR_w = \langle RHR \rangle_w - \langle RHR \rangle_{\text{control}}. \quad (3)$$

212 We compute the fraction of participants who have  $\Delta RHR \leq x$  bpm, computed from the  
213 bradycardia window, and compare it to the same fraction computed from data in the healthy  
214 window, where  $x$  is a threshold value plotted along the horizontal axis. We do a similar com-  
215 parison with the data in the tachycardia window. We compute the fraction of participants  
216 with  $\Delta RHR \geq x$  computed from the tachycardia window, and compare with the fraction  
217 computed from data in the healthy window. Fig. 5 shows this comparison. The curve  
218 plotted in red in Fig. 5(a) shows the fraction of individuals in the time window  $D_{+7} - D_{+21}$   
219 with  $\Delta RHR \leq x$  plotted along the horizontal axis. This should be compared with the curve  
220 plotted in green which is an estimate of how likely it is that such a low  $\Delta RHR$  may occur  
221 due to random chance. Fig. 5(b) shows a similar comparison, but for  $\Delta RHR \geq x$ , and  
222 considering the tachycardia window.

223 Interestingly, there is a correlation between the peak value of  $\Delta RHR$  measured during  
224 symptom onset (we use a 15 day window from  $D_{-5}$  to  $D_{+9}$ ) and the peak and minimum  
225 values of  $\Delta RHR$  measured in the second relative tachycardia window ( $D_{+22}$  to  $D_{+36}$ ) and the




FIG. 6. Correlation between the peak value of  $\Delta RHR$  measured during symptom onset, and (i) peak value of  $\Delta RHR$  in the second relative tachycardia window shown in red, (ii) minimum value of  $\Delta RHR$  measured in the relative bradycardia window shown in blue. The shaded areas represent the 1 standard deviation range.

226 relative bradycardia window ( $D_{+7}$  to  $D_{+21}$ ). Fig. 6 shows this correlation. The horizontal  
227 axis is  $\Delta RHR$  during symptom onset, while the vertical axis shows  $\Delta RHR$  during either the  
228 second tachycardia phase (red) or the bradycardia phase (blue). We see that  $\Delta RHR_{tachy}$   
229 measured in the second relative tachycardia phase is positively correlated with  $\Delta RHR_{symptom}$ ,  
230 the peak value observed at symptom onset. Similarly,  $\Delta RHR_{brady}$ , the minimum value  
231 observed during the relative bradycardia phase is positively correlated with  $\Delta RHR_{symptom}$ .  
232 This means that a low  $\Delta RHR$  at symptom onset is indicative of a decreased RHR in the  
233 relative bradycardia phase. An approximate estimate of  $\Delta RHR_{tachy}$  and  $\Delta RHR_{brady}$  may

234 be obtained by the following linear relations (with all measurements in bpm):

$$\begin{aligned}\Delta RHR_{\text{tachy}} &= 2.27 + 0.468 \Delta RHR_{\text{symptom}} \\ \Delta RHR_{\text{brady}} &= -6.67 + 0.622 \Delta RHR_{\text{symptom}}.\end{aligned}\tag{4}$$

235 **C. Comparison with other measurements**




FIG. 7. Excess fractional change in RMSSD and respiratory rate. Subplots (a) and (b) also show the excess fractional change in RHR (dashed black lines). Note that the RHR waveform is smoothed over time, resulting in a more rounded peak. Subplots (c) and (d) show the RMSSD and respiratory rate for male (green) and female (black) subjects respectively.

236 Let us now briefly consider 2 more health metrics: the heart rate variability quantified  
 237 by the root mean square of the successive differences (RMSSD) and the respiratory rate.

238 Fig. 7 shows the excess fractional change  $\Delta\xi$  in RMSSD (subplot (a)) and the respiratory  
239 rate (subplot (b)), plotted for symptomatic COVID-19. Also shown for comparison in  
240 dashed lines is the fractional change in RHR. The fractional change in RMSSD shows a  
241 similar time evolution as the RHR, except with opposite phase, i.e. when the RHR is  
242 elevated, the RMSSD is decreased and vice-versa. The relative bradycardia phase is seen  
243 to be accompanied by elevated heart rate variability, while the second relative tachycardia  
244 phase is associated with reduced heart rate variability. The variation is also of greater  
245 amplitude with the RMSSD compared to the RHR. The fractional change in the respiratory  
246 rate, on the other hand, does not show a similar time evolution. The respiratory rate is  
247 elevated during symptom onset, in response to the illness. It then decreases sharply, and  
248 then gradually returns to normal. Thus there is no equivalent of the relative bradycardia  
249 and second relative tachycardia phases with the respiratory rate.

#### 250 IV. DISCUSSION

251 Both COVID-19 and flu cases show 3 distinct phases:

- 252 • First relative tachycardia phase during symptom onset when the RHR is elevated above  
253 normal, reaching a local peak value  $A_{t1}$  at a time  $T_{t1}$  days after symptom onset, with  
254 a full width at half maximum  $W_{t1}$ . The peak value  $A_{t1}$  is higher in males compared  
255 to females, for COVID-19 ( $p$ -value  $< 0.0001$ ) and flu ( $p$ -value = 0.0118).
- 256 • Following this peak, the RHR decreases, and reaches a local minimum value  $A_b$  at  
257 a time  $T_b$  days after symptom onset. If  $A_b < 0$ , we refer to this phase as relative  
258 bradycardia, and define a full width at half minimum  $W_b$ . The condition  $A_b < 0$  is  
259 satisfied for females (averaged over all ages), for COVID-19 ( $p < 0.0001$ ), and for flu  
260 ( $p = 0.042$ ). The condition  $A_b < 0$  is not statistically significant for males (averaged  
261 over all ages), for either COVID-19 or flu.
- 262 • Following the minimum, the RHR increases, reaching a second local maximum  $A_{t2}$  at  
263 a time  $T_{t2}$  days from symptom onset, with a full width at half maximum  $W_{t2}$ . The  
264 peak value  $A_{t2}$  is higher in males compared to females, for COVID-19 ( $p < 0.0001$ )  
265 and flu ( $p = 0.0667$ ).

266 Fig. 3 shows  $\Delta\xi$  for male and female participants for different cases of COVID-19 severity,  
267 and for flu. Since these phases occur with both COVID-19 and flu, they are not novel to  
268 COVID-19. They can however, be more prominent in the case of COVID-19. It should  
269 be noted that flu has also been associated with cardiovascular disease<sup>37</sup>. It is also known  
270 that the autonomic nervous system plays a key role in sensing and responding to infection,  
271 with pathogens activating vagal signaling causing bradyarrhythmias<sup>38</sup>. It is intriguing that  
272 we see a statistically significant difference between male and female individuals, in the time  
273 variation of the RHR (Fig. 3) and the time variation of the RMSSD (Fig. 7).

274 The parameters that describe the time evolution of the RHR depend on sex, age, and  
275 disease severity and are tabulated in Tables III, IV and V. They are also plotted in Fig. 4 for  
276 different age groups for male and female individuals. The relative bradycardia minimum  $A_b$   
277 and the time to the minimum  $T_b$  are correlated with age (The Pearson  $r$  for the correlation  
278 between  $A_b$  and age was found to be  $r = 0.80$  for females and  $r = 0.97$  for males. The  
279 Pearson  $r$  for the correlation between  $T_b$  and age was found to be  $r = 0.98$  for females and  
280  $r = 0.77$  for males). The width of the first relative tachycardia peak  $W_{t1}$  is also correlated  
281 with age ( $r = 0.83$  for females, and  $r = 0.94$  for males).

282 Among the 3 phases, the relative tachycardia at symptom onset is the easiest to under-  
283 stand, and may be interpreted as an immune response to infection. More unexpected is  
284 the decrease in RHR, possibly resulting in transient relative bradycardia. Approximately  
285 1% of individuals experience a value of RHR that is at least 10 bpm lower than normal  
286 (see Fig. 5). Sinus bradycardia is known to occur during sleep in the case of COVID-19<sup>39</sup>.  
287 Since Fitbit's measurement of RHR is not the lowest value of heart rate, this raises the  
288 possibility that the heart rate during sleep may reach dangerously low values. It is crucial  
289 to be aware of this transient relative bradycardia phase, since certain medications used in  
290 the treatment of COVID-19 such as Remdesivir have been known to cause bradycardia<sup>40-42</sup>.  
291 Interestingly, mild cases of COVID-19 are more likely to present with relative bradycardia.  
292 It is also more likely to present in females compared to males. A possible explanation for  
293 this may be obtained from Fig. 6, and Table I. Fig. 6 shows that the peak RHR during  
294 symptom onset is positively correlated with the magnitude of the dip, i.e. a smaller peak  
295 RHR during symptom onset is associated with a larger (and possibly negative) dip. It is well  
296 known the heart rate is strongly linked to temperature, increasing by 8.5 bpm per 1 degree  
297 C increase in temperature, as found in one study<sup>43</sup>. As seen from Table I, males are more

298 likely to present with a fever compared to females. Similarly, fever is more common in severe  
299 cases compared to mild cases. Thus, females as well as mild cases presenting with a small  
300 RHR increase (or no increase) are more likely to experience a bradycardia dip compared to  
301 males, or severe cases. Similarly, Fig. 6 shows that the peak RHR during symptom onset is  
302 positively correlated with the height of the second tachycardia peak. As a result, the second  
303 tachycardia peak is higher in males, and for severe cases. The heart rate variability shows  
304 a similar time evolution as the resting heart rate, except with opposite phase. Fig. 7 shows  
305 the time evolution of the RMSSD (subplot (a)) and the respiratory rate (subplot (b)) with  
306 time. Unlike the RMSSD, the respiratory rate decreases monotonously past the initial peak.  
307 Subplots (c) and (d) show the variation of RMSSD and respiratory rate, for male and female  
308 subjects.

309 There are several limitations to the current work. A major concern is that we do not know  
310 whether the individuals who were diagnosed with COVID-19 and flu received medications  
311 to treat their illness, and what effects those medications may have had on their heart rate.  
312 The symptoms, severity, as well as symptom start date were all obtained from a survey,  
313 and could not be independently verified. We have also assumed that the participants were  
314 healthy prior to being diagnosed with COVID-19 or flu, and that the control group consisted  
315 of healthy individuals. Despite these limitations, the work presented in this article shows how  
316 COVID-19 and flu can alter the resting heart rate in the weeks/months following infection.  
317 This knowledge can be crucial in the case of patients with cardiac complications, or when  
318 patients are being treated with medication known to have cardiac effects.

## 319 **V. CONTRIBUTORS**

320 A.N. and H.W.-S. had access to all the data and verified the results shown. A.N. was  
321 responsible for part of the scientific analysis and for preparing the first version of the  
322 manuscript. H.W.-S. was responsible for part of the scientific analysis. C.H. led the Fitbit  
323 COVID-19 study, and provided valuable insights and feedback on the analysis and presen-  
324 tation of results.

## 325 VI. DECLARATION OF INTERESTS

326 All authors are employed by Fitbit Research, Google LLC.

## 327 VII. DATA SHARING

328 Our consent form and the protocol allow us to make the raw data available to two  
329 academic members of our research consortium, namely Stanford University, and Scripps  
330 Translational Research Institute. Fitbit’s privacy policy does not permit us to make the  
331 raw data or aggregate data available to third parties including researchers, outside of our  
332 web API Oauth 2.0 consent process. For specific questions, contact Fitbit at [https://  
333 healthsolutions.fitbit.com/contact/](https://healthsolutions.fitbit.com/contact/).

## 334 VIII. ACKNOWLEDGMENTS

335 A.N., H.W.-S. and C.H. acknowledge funding from Fitbit Research, Google LLC. We  
336 thank members of the Fitbit Research team for many helpful discussions.

---

337 \* [anatarajan@google.com](mailto:anatarajan@google.com)

338 <sup>1</sup> S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, W. Gong, X. Liu, J. Liang, Q. Zhao, H. Huang,  
339 B. Yang, and C. Huang, “Association of Cardiac Injury With Mortality in Hospitalized Patients  
340 With COVID-19 in Wuhan, China,” *JAMA Cardiol* **5**, 802–810 (2020).

341 <sup>2</sup> C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng,  
342 T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie,  
343 G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao, “Clinical features of patients infected  
344 with 2019 novel coronavirus in Wuhan, China,” *Lancet* **395**, 497–506 (2020).

345 <sup>3</sup> D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong,  
346 Y. Zhao, Y. Li, X. Wang, and Z. Peng, “Clinical Characteristics of 138 Hospitalized Patients  
347 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China,” *JAMA* **323**, 1061–1069  
348 (2020).

- 349 <sup>4</sup> B. Siripanthong, S. Nazarian, D. Muser, R. Deo, P. Santangeli, M. Y. Khanji, L. T. Cooper, and  
350 C. A. A. Chahal, “Recognizing COVID-19-related myocarditis: The possible pathophysiology  
351 and proposed guideline for diagnosis and management,” *Heart Rhythm* **17**, 1463–1471 (2020).
- 352 <sup>5</sup> E. J. Coromilas, S. Kochav, I. Goldenthal, A. Biviano, H. Garan, S. Goldbarg, J. H. Kim,  
353 I. Yeo, C. Tracy, S. Ayanian, J. Akar, A. Singh, S. Jain, L. Zimmerman, M. Pimentel, S. Osswald,  
354 R. Twerenbold, N. Schaerli, L. Crotti, D. Fabbri, G. Parati, Y. Li, F. Atienza, E. Zatarain,  
355 G. Tse, K. S. K. Leung, M. E. Guevara-Valdivia, C. A. Rivera-Santiago, K. Soejima, P. De Fil-  
356 ippo, P. Ferrari, G. Malanchini, P. Kanagaratnam, S. Khawaja, G. W. Mikhail, M. Scanavacca,  
357 L. Abrahão Hajjar, B. Rizerio, L. Sacilotto, R. Mollazadeh, M. Eslami, V. Laleh Far, A. V.  
358 Mattioli, G. Boriani, F. Migliore, A. Cipriani, F. Donato, P. Compagnucci, M. Casella,  
359 A. Dello Russo, J. Coromilas, A. Aboyme, C. G. O’Brien, F. Rodriguez, P. J. Wang, A. Nani-  
360 wadekar, M. Moey, C. S. Kow, W. K. Cheah, A. Auricchio, G. Conte, J. Hwang, S. Han,  
361 P. E. Lazzarini, F. Franchi, A. Santoro, P. L. Capecchi, J. A. Joglar, A. G. Rosenblatt,  
362 M. Zardini, S. Bricoli, R. Bonura, J. Echarte-Morales, T. Benito-González, C. Minguito-Carazo,  
363 F. Fernández-Vázquez, and E. Y. Wan, “Worldwide Survey of COVID-19-Associated Arrhyth-  
364 mias,” *Circ Arrhythm Electrophysiol* **14**, e009458 (2021).
- 365 <sup>6</sup> A. N. Kochi, A. P. Tagliari, G. B. Forleo, G. M. Fassini, and C. Tondo, “Cardiac and arrhythmic  
366 complications in patients with COVID-19,” *J Cardiovasc Electrophysiol* **31**, 1003–1008 (2020).
- 367 <sup>7</sup> B. Long, W. J. Brady, A. Koyfman, and M. Gottlieb, “Cardiovascular complications in COVID-  
368 19,” *Am J Emerg Med* **38**, 1504–1507 (2020).
- 369 <sup>8</sup> A. Y. Cizgici, H. Zencirkiran Agus, and M. Yildiz, “COVID-19 myopericarditis: It should be  
370 kept in mind in today’s conditions,” *Am J Emerg Med* **38**, 5–1547 (2020).
- 371 <sup>9</sup> M. Linschoten, S. Peters, M. van Smeden, L. S. Jewbali, J. Schaap, H. M. Siebelink, P. C.  
372 Smits, R. G. Tieleman, P. van der Harst, W. H. van Gilst, and F. W. Asselbergs, “Cardiac  
373 complications in patients hospitalised with COVID-19,” *Eur Heart J Acute Cardiovasc Care* **9**,  
374 817–823 (2020).
- 375 <sup>10</sup> M. Sahranavard, A. Akhavan Rezayat, M. Zamiri Bidary, A. Omranzadeh, F. Rohani,  
376 R. Hamidi Farahani, E. Hazrati, S. H. Mousavi, M. Afshar Ardalan, S. Soleiman-Meigooni,  
377 S. J. Hosseini-Shokouh, Z. Hejripour, E. Nassireslami, R. Laripour, A. Salarian, A. Nourmo-  
378 hammadi, and R. Mosaed, “Cardiac Complications in COVID-19: A Systematic Review and  
379 Meta-analysis,” *Arch Iran Med* **24**, 152–163 (2021).



- 380 11 .
- 381 12 G. Capoferri, M. Osthoff, A. Egli, M. Stoeckle, and S. Bassetti, “Relative bradycardia in  
382 patients with COVID-19,” *Clin Microbiol Infect* **27**, 295–296 (2021).
- 383 13 S. Douedi, A. Mararenko, A. Alshami, M. Al-Azzawi, F. Ajam, S. Patel, H. Douedi, and  
384 D. Calderon, “COVID-19 induced bradyarrhythmia and relative bradycardia: An overview,” *J*  
385 *Arrhythm* **37**, 888–892 (2021).
- 386 14 A. Oliva, C. Franchi, M. C. Gatto, G. Galardo, F. Pugliese, and C. Mastroianni, “Prevalence  
387 and clinical significance of relative bradycardia at hospital admission in patients with coron-  
388 avirus disease 2019 (COVID-19),” *Clin Microbiol Infect* **27**, 1185–1187 (2021).
- 389 15 E. A. Amaratunga, D. S. Corwin, L. Moran, and R. Snyder, “Bradycardia in Patients With  
390 COVID-19: A Calm Before the Storm?” *Cureus* **12**, e8599 (2020).
- 391 16 M. Amir, H. Yoseph, A. T. A. Farisi, J. K. P. Phie, and A. T. S. Adam, “Symptomatic  
392 Bradycardia in Covid-19 Hospitalized Patients: A Case Series,” *Int J Infect Dis* **111**, 1–4  
393 (2021).
- 394 17 W. Elikowski, N. Fertala, M. Zawodna-Marszalek, J. Rajewska-Tabor, W. Swidurski, D. Wa-  
395 jdlich, A. Marszalek, P. Skrzywanek, M. Pyda, and M. Zytkeiwicz, “Marked self-limiting sinus  
396 bradycardia in COVID-19 patients not requiring therapy in the intensive care unit - case series  
397 report,” *Pol Merkur Lekarski* **49**, 295–302 (2021).
- 398 18 A. Srinivasan, T. Pansuriya, B. Wilson, S. T. Sarva, T. Jayaram, S. Alim, R. Kesavan, and  
399 S. Raza, “Systemic Inflammation-Related Bradycardia in COVID-19,” *Case Rep Cardiol* **2021**,  
400 9986955 (2021).
- 401 19 M. Zhou, C. K. Wong, K. C. Un, Y. M. Lau, J. C. Lee, F. C. Tam, Y. M. Lau, W. H. Lai,  
402 A. R. Tam, Y. Y. Lam, P. Pang, T. Tong, M. Tang, H. F. Tse, D. Ho, M. Y. Ng, E. W. Chan,  
403 I. C. K. Wong, C. P. Lau, I. F. Hung, and C. W. Siu, “Cardiovascular sequelae in uncomplicated  
404 COVID-19 survivors,” *PLoS One* **16**, e0246732 (2021).
- 405 20 T. Guo, Y. Fan, M. Chen, X. Wu, L. Zhang, T. He, H. Wang, J. Wan, X. Wang, and Z. Lu,  
406 “Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019  
407 (COVID-19),” *JAMA Cardiol* **5**, 811–818 (2020).
- 408 21 A. Bhatla, M. M. Mayer, S. Adusumalli, M. C. Hyman, E. Oh, A. Tierney, J. Moss, A. A.  
409 Chahal, G. Anesi, S. Denduluri, C. M. Domenico, J. Arkles, B. S. Abella, J. R. Bullinga, D. J.  
410 Callans, S. Dixit, A. E. Epstein, D. S. Frankel, F. C. Garcia, R. Kumareswaram, S. Nazarian,

- 411 M. P. Riley, P. Santangeli, R. D. Schaller, G. E. Supple, D. Lin, F. Marchlinski, and R. Deo,  
412 “COVID-19 and cardiac arrhythmias,” *Heart Rhythm* **17**, 1439–1444 (2020).
- 413 <sup>22</sup> P. Dherange, J. Lang, P. Qian, B. Oberfeld, W. H. Sauer, B. Koplán, and U. Tedrow, “Ar-  
414 rhythmias and COVID-19: A Review,” *JACC Clin Electrophysiol* **6**, 1193–1204 (2020).
- 415 <sup>23</sup> G. Peigh, M. V. Leya, J. R. Baman, E. P. Cantey, B. P. Knight, and J. D. Flaherty, “Novel  
416 coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series,” *Eur Heart J Case*  
417 *Rep* **4**, 1–6 (2020).
- 418 <sup>24</sup> D. J. Miller, J. V. Capodilupo, M. Lastella, C. Sargent, G. D. Roach, V. H. Lee, and E. R.  
419 Capodilupo, “Analyzing changes in respiratory rate to predict the risk of COVID-19 infection,”  
420 *PLoS One* **15**, e0243693 (2020).
- 421 <sup>25</sup> T. Mishra, M. Wang, A. A. Metwally, G. K. Bogu, A. W. Brooks, A. Bahmani, A. Alavi, A. Celli,  
422 E. Higgs, O. Dagan-Rosenfeld, B. Fay, S. Kirkpatrick, R. Kellogg, M. Gibson, T. Wang, E. M.  
423 Hunting, P. Mamic, A. B. Ganz, B. Rolnik, X. Li, and M. P. Snyder, “Pre-symptomatic  
424 detection of COVID-19 from smartwatch data,” *Nat Biomed Eng* **4**, 1208–1220 (2020).
- 425 <sup>26</sup> G. Quer, J. M. Radin, M. Gadaleta, K. Baca-Motes, L. Ariniello, E. Ramos, V. Kheterpal, E. J.  
426 Topol, and S. R. Steinhubl, “Wearable sensor data and self-reported symptoms for COVID-19  
427 detection,” *Nat Med* **27**, 73–77 (2021).
- 428 <sup>27</sup> A. Natarajan, H. W. Su, and C. Heneghan, “Assessment of physiological signs associated with  
429 COVID-19 measured using wearable devices,” *NPJ Digit Med* **3**, 156 (2020).
- 430 <sup>28</sup> A. Natarajan, H. W. Su, C. Heneghan, L. Blunt, C. O’Connor, and L. Niehaus, “Measurement  
431 of respiratory rate using wearable devices and applications to COVID-19 detection,” *NPJ Digit*  
432 *Med* **4**, 136 (2021).
- 433 <sup>29</sup> J. C. Miller, D. Skoll, and L. A. Saxon, “Home Monitoring of Cardiac Devices in the Era of  
434 COVID-19,” *Curr Cardiol Rep* **23**, 1 (2020).
- 435 <sup>30</sup> J. M. Radin, G. Quer, E. Ramos, K. Baca-Motes, M. Gadaleta, E. J. Topol, and S. R. Steinhubl,  
436 “Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19  
437 Infection,” *JAMA Netw Open* **4**, e2115959 (2021).
- 438 <sup>31</sup> Y. Ostchega, K. S. Porter, J. Hughes, C. F. Dillon, and T. Nwankwo, “Resting pulse rate  
439 reference data for children, adolescents, and adults: United States, 1999–2008,” *Natl Health*  
440 *Stat Report*, 1–16 (2011).

- 441 <sup>32</sup> A. Russell, C. Heneghan, and S. Venkatraman, “Investigation of an estimate of daily rest-  
442 ing heart rate using a consumer wearable device,” medRxiv (2019), 10.1101/19008771,  
443 <https://www.medrxiv.org/content/early/2019/10/18/19008771.full.pdf>.
- 444 <sup>33</sup> G. Quer, P. Gouda, M. Galarnyk, E. J. Topol, and S. R. Steinhubl, “Inter- and intraindividual  
445 variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time  
446 of year: Retrospective, longitudinal cohort study of 92,457 adults,” PLoS One **15**, e0227709  
447 (2020).
- 448 <sup>34</sup> R. G. Miller, “The jackknife—a review,” Biometrika **61**, 1–15 (1974).
- 449 <sup>35</sup> B. Efron, “Nonparametric estimates of standard error: The jackknife, the bootstrap and other  
450 methods,” Biometrika **68**, 589–599 (1981).
- 451 <sup>36</sup> A. Natarajan, A. Pantelopoulos, H. Emir-Farinas, and P. Natarajan, “Heart rate variability  
452 with photoplethysmography in 8 million individuals: a cross-sectional study,” Lancet Digit  
453 Health **2**, e650–e657 (2020).
- 454 <sup>37</sup> J. L. Nguyen, W. Yang, K. Ito, T. D. Matte, J. Shaman, and P. L. Kinney, “Seasonal Influenza  
455 Infections and Cardiovascular Disease Mortality,” JAMA Cardiol **1**, 274–281 (2016).
- 456 <sup>38</sup> K. D. Fairchild, V. Srinivasan, J. R. Moorman, R. P. Gaykema, and L. E. Goehler, “Pathogen-  
457 induced heart rate changes associated with cholinergic nervous system activation,” Am J Physiol  
458 Regul Integr Comp Physiol **300**, R330–339 (2011).
- 459 <sup>39</sup> L. Hu, L. Gong, Z. Jiang, Q. Wang, Y. Zou, and L. Zhu, “Clinical analysis of sinus bradycardia  
460 in patients with severe COVID-19 pneumonia,” Crit Care **24**, 257 (2020).
- 461 <sup>40</sup> A. K. Gupta, B. M. Parker, V. Priyadarshi, and J. Parker, “Cardiac Adverse Events With  
462 Remdesivir in COVID-19 Infection,” Cureus **12**, e11132 (2020).
- 463 <sup>41</sup> M. I. Sanchez-Codez, M. Rodriguez-Gonzalez, and I. Gutierrez-Rosa, “Severe sinus bradycardia  
464 associated with Remdesivir in a child with severe SARS-CoV-2 infection,” Eur J Pediatr **180**,  
465 1627 (2021).
- 466 <sup>42</sup> J. P. Jacinto, M. Patel, J. Goh, and K. Yamamura, “Remdesivir-induced symptomatic brady-  
467 cardia in the treatment of COVID-19 disease,” HeartRhythm Case Rep **7**, 514–517 (2021).
- 468 <sup>43</sup> J. Karjalainen and M. Viitasalo, “Fever and cardiac rhythm,” Arch Intern Med **146**, 1169–1171  
469 (1986).